Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsResearch Summary
Analyzed using Evidence Intelligence™
Luseogliflozin improves glycemic control in older adults with T2D
Last updated July 5, 2026
Key finding
HbA1c decreased by 0.14% from baseline to week 52.
This study investigated the effects of Luseogliflozin combined with leucine-enriched amino acid supplementation and exercise in older adults with type 2 diabetes. It found a decrease in HbA1c and body weight over 52 weeks.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save this study and add notes to your research library.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of Luseogliflozin combined with leucine-enriched amino acid supplementation and exercise in older adults with type 2 diabetes. It found a decrease in HbA1c and body weight over 52 weeks.
Clinical relevance
These findings suggest that Luseogliflozin, when combined with exercise and dietary supplementation, can help manage blood sugar levels and weight in older adults with type 2 diabetes. This is particularly important as effective management of diabetes can reduce the risk of complications and improve overall health in this population.
Keep in mind
The study did not include a large sample size. Some outcomes did not reach statistical significance. Findings may not be generalizable to all older adults with diabetes.
Published in
Journal Reference
Publication details and source links for this paper.
Yoshihiro T, Makoto H, Takehiro K, et al. Luseogliflozin Combined with Leucine-Enriched Amino Acid Supplementation and Exercise in Older Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2026;28(4):3439-3444. doi:10.1111/dom.70494
Main Effects
HbA1c decreased by 0.14% (p=0.0043)
Body weight decreased by 1.64 kg (p=0.0248)
Body fat mass decreased by 0.89 kg (p=0.0897)
HbA1c increased by 0.23% in the control group
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Luseogliflozin and Body fat mass, Body weight, Five-times Sit-to-Stand Test, and 3 more.
This study contributes evidence to
Primary intervention
Luseogliflozin
Primary outcomes
- Body fat mass
- Body weight
- Five-times Sit-to-Stand Test
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
6
Evidence pairs
288
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Track related evidence
Follow the evidence behind this paper in your workspace.
Primary evidence
Evidence relationship
DPP-4 Inhibitors and HbA1c
Related evidence
Evidence relationship
DPP-4 Inhibitors and Body Weight
Follow evidence
Evidence relationship
DPP-4 Inhibitors and Body Composition
Follow evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsFive-times Sit-to-Stand Test
Luseogliflozin → Five-times Sit-to-Stand Test
Luseogliflozin → Five-times Sit-to-Stand Test
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence detailsUnlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- HbA1c decreased by 0.14% in the treatment group.
- Body weight reduced by 1.64 kg after 52 weeks.
- Control group experienced an increase in HbA1c by 0.23%.
Who this applies to
- Older adults aged 65 and above
- Individuals diagnosed with type 2 diabetes
Keep in Mind
- Results may not apply to younger populations.
- The study's sample size was limited, affecting generalizability.
- Not all measured outcomes showed significant changes.
Between the Lines
- The study did not include a large sample size.
- Some outcomes did not reach statistical significance.
- Findings may not be generalizable to all older adults with diabetes.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Body Composition, DPP-4 Inhibitors and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceDPP-4 Inhibitors → Body Composition
Medications
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Detailed evidenceDPP-4 Inhibitors → Body Weight
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Composition Evidence Hub
All studies measuring Body Composition
1 studies
outcome_hubMeasures Body Composition as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
DPP-4 Inhibitors Evidence Hub
All studies on DPP-4 Inhibitors
1 studies
intervention_hubContributes to DPP-4 Inhibitors evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Luseogliflozin and Body fat mass
Intervention: LuseogliflozinOutcome: Body fat mass
1 results
All studies on Luseogliflozin and Body weight
Intervention: LuseogliflozinOutcome: Body weight
1 results
All studies on Luseogliflozin
Intervention: Luseogliflozin
1 results
All studies measuring Body fat mass
Outcome: Body fat mass
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors improve HbA1c?
Strong Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors affect body weight?
Strong Evidence
DPP-4 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 4 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve body composition?
Emerging Evidence
Current evidence does not show a clear benefit of DPP-4 Inhibitors for Body Composition.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
- 2
Lean body mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does DPP-4 Inhibitors improve muscular strength?
Emerging Evidence
Current evidence does not show a clear benefit of DPP-4 Inhibitors for Muscular Strength.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Handgrip Strength
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesLifestyle calorie-carbohydrate plans improved type 2 diabetes remission versus usual careLifestyle changes plus probiotic use were linked with better HbA1c in one man with type 2 diabetesAI virtual trials match real trial results for GLP-1 vs insulin in type 2 diabetesDietary supplements may lower diabetes risk in prediabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.